Valuation: Axsome Therapeutics, Inc.

Market Cap 10.86B 9.44B 8.81B 8.09B 15.25B 1,035B 15.52B 104B 40.69B 516B 40.79B 39.89B 1,703B P/E 2026 *
-102x
P/E 2027 * 38.2x
Enterprise Value 10.75B 9.34B 8.72B 8.01B 15.1B 1,025B 15.36B 103B 40.28B 511B 40.38B 39.48B 1,685B EV / Sales 2026 *
11x
EV / Sales 2027 * 6.56x
Free-Float
84.36%
Yield 2026 *
-
Yield 2027 * -
1 day-3.19%
1 week-11.47%
Current month-3.19%
1 month-13.62%
3 months+2.18%
6 months+12.64%
Current year+15.55%
1 week 206.94
Extreme 206.94
235.91
1 month 206.94
Extreme 206.94
252.6
Current year 152.28
Extreme 152.28
260.19
1 year 101.11
Extreme 101.11
260.19
3 years 55.02
Extreme 55.02
260.19
5 years 19.38
Extreme 19.38
260.19
10 years 1.94
Extreme 1.94
260.19
Manager TitleAgeSince
Chief Executive Officer 57 2012-01-11
Director of Finance/CFO 51 2018-05-15
Chief Operating Officer 42 2014-03-31
Director TitleAgeSince
Chairman 57 2012-01-11
Director/Board Member 64 2014-11-30
Director/Board Member 58 2014-11-30
Date Insider Type Main position Quantity % Market Cap.
7/1/26 Fiscal year

Chief Executive Officer

148,998 0.2895%
6/5/26 Free

Director

1,721 0.0033%
4/22/26 Fiscal year

Executive/Senior Manager

22,500 0.0440%
Change 5-day change 1-year change 3-year change Capi.($)
-3.19%-11.47%+104.85%+180.34% 10.86B
-0.44%+13.80%+35.85%-1.58% 75.81B
+1.58%-10.11%+21.80%+182.68% 48.57B
-4.18%+42.30%+42.30%+42.30% 46.01B
+3.64%+7.79%-51.37%-51.41% 41.66B
-0.56%+0.84%+52.95%-24.62% 29.82B
-0.91%-0.37%+56.67%+82.26% 24.01B
+0.58%-0.88%+99.75%-49.85% 22.01B
+0.81%-3.56%-6.67%+164.33% 19.09B
+0.23%-6.73%+61.38%+115.33% 15.83B
Average -0.26%-1.91%+41.75%+63.98% 33.37B
Weighted average by Cap. -0.12%+0.53%+32.07%+46.82%

Financials

2026 *2027 *
Net sales 979M 851M 794M 729M 1.38B 93.32B 1.4B 9.37B 3.67B 46.54B 3.68B 3.6B 153B 1.6B 1.39B 1.3B 1.19B 2.24B 152B 2.28B 15.27B 5.98B 75.88B 6B 5.86B 250B
Net income -108M -93.97M -87.73M -80.54M -152M -10.31B -155M -1.03B -405M -5.14B -406M -397M -16.95B 308M 267M 250M 229M 432M 29.33B 440M 2.94B 1.15B 14.63B 1.16B 1.13B 48.24B
Net Debt -111M -96.21M -89.82M -82.46M -155M -10.55B -158M -1.06B -415M -5.26B -416M -407M -17.35B -394M -342M -320M -293M -553M -37.54B -563M -3.77B -1.48B -18.72B -1.48B -1.45B -61.74B
Logo Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. It is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia.
Employees
1,220
Date Price Change Volume
26-08-03 $211.04 -3.19% 962,867
26-07-31 $217.99 -7.10% 782,168
26-07-30 $234.64 +3.17% 714,361
26-07-29 $227.42 -2.89% 523,066
26-07-28 $234.20 -1.75% 404,143
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
211.04USD
Average target price
282.32USD
Spread / Average Target
+33.78%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AXSM Stock